- Home
- NRO vs CLLS Comparison
NRO vs CLLS Comparison
Compare NRO & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRO
- CLLS
- Stock Information
- Founded
- NRO 2003
- CLLS 1999
- Country
- NRO United States
- CLLS France
- Employees
- NRO N/A
- CLLS N/A
- Industry
- NRO Finance/Investors Services
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- NRO Finance
- CLLS Health Care
- Exchange
- NRO Nasdaq
- CLLS Nasdaq
- Market Cap
- NRO 156.7M
- CLLS 144.4M
- IPO Year
- NRO N/A
- CLLS 2007
- Fundamental
- Price
- NRO $3.19
- CLLS $1.52
- Analyst Decision
- NRO
- CLLS Buy
- Analyst Count
- NRO 0
- CLLS 3
- Target Price
- NRO N/A
- CLLS $6.67
- AVG Volume (30 Days)
- NRO 239.4K
- CLLS 48.8K
- Earning Date
- NRO 01-01-0001
- CLLS 05-12-2025
- Dividend Yield
- NRO 11.41%
- CLLS N/A
- EPS Growth
- NRO N/A
- CLLS N/A
- EPS
- NRO N/A
- CLLS N/A
- Revenue
- NRO N/A
- CLLS $54,747,000.00
- Revenue This Year
- NRO N/A
- CLLS $48.52
- Revenue Next Year
- NRO N/A
- CLLS $5.17
- P/E Ratio
- NRO N/A
- CLLS N/A
- Revenue Growth
- NRO N/A
- CLLS 351.26
- 52 Week Low
- NRO $2.51
- CLLS $1.10
- 52 Week High
- NRO $3.45
- CLLS $2.81
- Technical
- Relative Strength Index (RSI)
- NRO 48.24
- CLLS 53.80
- Support Level
- NRO $3.16
- CLLS $1.46
- Resistance Level
- NRO $3.24
- CLLS $1.60
- Average True Range (ATR)
- NRO 0.05
- CLLS 0.08
- MACD
- NRO -0.00
- CLLS -0.01
- Stochastic Oscillator
- NRO 36.67
- CLLS 65.26
About NRO Neuberger Berman Real Estate Securities Income Fund Inc.
NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND INC is a closed-end management investment company that invests mainly in securities issued by real estate companies, including real estate investment trusts (REITs). Its primary objective is to gain high current income with capital appreciation being the second. Under normal market conditions, the Fund invests at least 90% of its total assets in income-producing common equity securities, preferred securities, convertible securities and non-convertible debt securities issued by real estate companies, including real estate investment trusts ("REITs").
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.